Skip to content
Sign in

AKBA · NASDAQ

Akebia Therapeutics (AKBA) Stock Price & Fundamentals

$783.05−0.51%−$4.00End-of-day price as of Oct 9, 2026

Akebia Therapeutics (AKBA) closed at $783.05 on Oct 9, 2026, down 0.51% from the previous close of $787.05.

Share price, past year

1Y +19.47%

52-week range $647.09 – $793.03. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$783.05
Sep 30, 2026$768.65
Aug 31, 2026$736.43
Jul 31, 2026$739.28
Jun 30, 2026$759.15
May 29, 2026$743.58
Apr 30, 2026$738.89
Mar 31, 2026$693.33
Feb 27, 2026$704.54
Jan 30, 2026$717.48
Dec 31, 2025$694.09
Nov 28, 2025$671.23
Oct 31, 2025$661.61

Key statistics

Market cap
$212.79B
P/E (TTM)
—
EPS (TTM)
−$0.11
Revenue (TTM)
$219.06M
Net income (TTM)
−$29.67M
Shares outstanding
271.7M
Dividend yield
—
52-week range
$647.09 – $793.03

Akebia Therapeutics's market cap is $212.79B, based on a share price of $783.05 and 271.7M shares outstanding as of Jun 30, 2026.

Financials

Akebia Therapeutics reported revenue of $236.20M for fiscal 2025, up 47.46% from fiscal 2024.

Akebia Therapeutics reported a net loss of $5.35M in fiscal 2025.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Akebia Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$236.20M+47.5%−$5.35M−2.3%−$0.02$67.70M
FY2024ended Dec 31, 2024$160.18M−17.7%−$69.41M−43.3%−$0.33−$40.69M
FY2023ended Dec 31, 2023$194.62M−33.5%−$51.93M−26.7%−$0.28−$23.38M
FY2022ended Dec 31, 2022$292.48M+38.2%−$94.23M−32.2%−$0.52−$73.27M
FY2021ended Dec 31, 2021$211.65M−28.2%−$282.02M−133.3%−$1.70−$253.02M
FY2020ended Dec 31, 2020$294.64M−12.1%−$384.84M−130.6%−$2.78−$110.71M
FY2019ended Dec 31, 2019$335.00M+61.3%−$279.66M−83.5%−$2.36−$264.10M
FY2018ended Dec 31, 2018$207.74M+14.6%−$143.59M−69.1%−$2.47−$99.10M
FY2017ended Dec 31, 2017$181.23M+11,706.3%−$73.67M−40.7%−$1.69−$57.78M
FY2016ended Dec 31, 2016$1.54M—−$135.75M−8,843.5%−$3.60$55.24M
Akebia Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$49.13M−$8.91M−$0.03
Q1 FY2026ended Mar 31, 2026$53.54M−$9.05M−$0.03
Q4 FY2025ended Dec 31, 2025$57.62M−$12.24M−$0.05
Q3 FY2025ended Sep 30, 2025$58.77M$540.00K$0.00
Q2 FY2025ended Jun 30, 2025$62.47M$247.00K$0.00
Q1 FY2025ended Mar 31, 2025$57.34M$6.11M$0.03
Q4 FY2024ended Dec 31, 2024$46.50M−$22.80M−$0.10
Q3 FY2024ended Sep 30, 2024$37.43M−$20.04M−$0.10

Company profile

Name
Akebia Therapeutics, Inc.
Ticker
AKBA
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
245 First Street, Cambridge, MA 02142
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001517022

Recent SEC filings

Frequently asked questions

What is Akebia Therapeutics's stock price?

Akebia Therapeutics (AKBA) closed at $783.05 on Oct 9, 2026, down 0.51% from the previous close of $787.05.

What is Akebia Therapeutics's market cap?

Akebia Therapeutics's market cap is $212.79B, based on a share price of $783.05 and 271.7M shares outstanding as of Jun 30, 2026.

How much revenue does Akebia Therapeutics make?

Akebia Therapeutics reported revenue of $236.20M for fiscal 2025, up 47.46% from fiscal 2024.

Does Akebia Therapeutics pay a dividend?

Akebia Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Akebia Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures